-
1
-
2
-
3Academic Journal
Authors: I. A. Mazerkina, I. G. Davydov, O. S. Alyautdina, И. А. Мазеркина, И. Г. Давыдов, О. С. Аляутдина
Contributors: The study reported in this publication was carried out as part of publicly funded research project No. 056-00026-24-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D reporting No. 124022300127-0)., Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00026-24-00 на проведение прикладных научных исследований (номер государственного учета НИР 124022300127-0).
Source: Safety and Risk of Pharmacotherapy; Том 12, № 2 (2024); 214-229 ; Безопасность и риск фармакотерапии; Том 12, № 2 (2024); 214-229 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2024-12-2
Subject Terms: женщины, combined oral contraceptives, oestrogens, progestogens, female infertility, hyperandrogenism, hirsutism, metabolic syndrome, safety of combined oral contraceptives, women, комбинированные оральные контрацептивы, эстрогены, прогестагены, женское бесплодие, гиперандрогения, гирсутизм, метаболический синдром, безопасность комбинированных оральных контрацептивов
File Description: application/pdf
Relation: https://www.risksafety.ru/jour/article/view/426/1156; https://www.risksafety.ru/jour/article/downloadSuppFile/426/518; Адамян ЛВ, Андреева ЕН, Абсатарова ЮС, Григорян ОР, Дедов ИИ, Мельниченко ГА и др. Клинические рекомендации «Синдром поликистозных яичников». Проблемы эндокринологии. 2022;68(2):112–27. https://doi.org/10.14341/probl12874; Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol. 2023;189(2):G43–G64. https://doi.org/10.1093/ejendo/lvad096; Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome — Part 1. Endocr Pract. 2015;21(11):1291–300. https://doi.org/10.4158/EP15748.DSC; Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome — Part 2. Endocr Pract. 2015;21(12):1415–26. https://doi.org/10.4158/EP15748.DSCPT2; Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41–7. https://doi.org/10.1093/humrep/deh098; Mumusoglu S, Yildiz BO. Polycystic ovary syndrome phenotypes and prevalence: differential impact of diagnostic criteria and clinical versus unselected population. Curr Opin Endocr Metab Res. 2020;12:66–71. https://doi.org/10.1016/j.coemr.2020.03.004; Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–55. https://doi.org/10.1093/humrep/dew218; Emanuel RHK, Roberts J, Docherty PD, Lunt H, Campbell RE, Möller K. A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions. Front Endocrinol (Lausanne). 2022;13:1017468. https://doi.org/10.3389/fendo.2022.1017468; Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al. Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(4):E628–37. https://doi.org/10.1210/jc.2012-3908; Bremer AA, Miller WL. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil Steril. 2008;89(5):1039–48. https://doi.org/10.1016/j.fertnstert.2008.02.091; Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence. Hum Reprod Update. 2011;17(1):17–33. https://doi.org/10.1093/humupd/dmq032; Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics (São Paulo). 2015;70(11):765–9. https://doi.org/10.6061/clinics/2015(11)09; Krentowska A, Kowalska I. Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome. Diabetes Metab Res Rev. 2022;38(1):e3464. https://doi.org/10.1002/dmrr.3464; Jacewicz-Święcka M, Kowalska I. Changes in metabolic profile in the women with a history of PCOS-A long-term follow-up study. J Clin Med. 2020;9(10):3367. https://doi.org/10.3390/jcm9103367; Wang Y, Ni Z, Li K. The prevalence of anxiety and depression of different severity in women with polycystic ovary syndrome: a meta-analysis. Gynecol Endocrinol. 2021;37(12):1072–8. https://doi.org/10.1080/09513590.2021.1942452; Brutocao C, Zaiem F, Alsawas M, Morrow AS, Murad MH, Javed A. Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2018;62(2):318–25. https://doi.org/10.1007/s12020-018-1692-3; Bellver J, Rodríguez-Tabernero L, Robles A, Muñoz E, Martínez F, Landeras J, et al. Polycystic ovary syndrome throughout a woman’s life. J Assist Reprod Genet. 2018;35(1):25–39. https://doi.org/10.1007/s10815-017-1047-7; Meczekalski B, Pérez-Roncero GR, López-Baena MT, Chedraui P, Pérez-López FR. The polycystic ovary syndrome and gynecological cancer risk. Gynecol Endocrinol. 2020;36(4):289–93. https://doi.org/10.1080/09513590.2020.1730794; Yin W, Falconer H, Yin L, Xu L, Ye W. Association between polycystic ovary syndrome and cancer risk. JAMA Oncol. 2019;5(1):106–7. https://doi.org/10.1001/jamaoncol.2018.5188; Сухих ГТ, Прилепская ВН, ред. Национальные медицинские критерии приемлемости методов контрацепции. М.; 2023. EDN: EFKVBW; Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J. Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk. Front Endocrinol (Lausanne). 2021;12:769187. https://doi.org/10.3389/fendo.2021.769187; Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27(1):13–24. https://doi.org/10.1016/j.beem.2012.09.004; Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas. 2003;46 Suppl 1:S7–S16. https://doi.org/10.1016/j.maturitas.2003.09.014; Seidman L, Kroll R, Howard B, Ricciotti N, Hsieh J, Weiss H. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial. Contraception. 2015;91(6):495–502. https://doi.org/10.1016/j.contraception.2015.03.001; Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999;181(5 Pt 1):1263–9. https://doi.org/10.1016/s0002-9378(99)70120-1; Fraser IS, Römer T, Parke S, Zeun S, Mellinger U, Machlitt A, Jensen JT. Effective treatment of heavy and/ or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod. 2011;26(10):2698–708. https://doi.org/10.1093/humrep/der224; Klipping C, Duijkers I, Trummer D, Marr J. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception. 2008;78(1):16–25. https://doi.org/10.1016/j.contraception.2008.02.019; Ferriman D, Gallwey Jd. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440–7. https://doi.org/10.1210/jcem-21-11-1440; Bienenfeld A, Azarchi S, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Androgens in women: androgen-mediated skin disease and patient evaluation. J Am Acad Dermatol. 2019;80(6):1497–506. https://doi.org/10.1016/j.jaad.2018.08.062; Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. https://doi.org/10.1038/nrdp.2016.57; Pasquali R, Gambineri A. Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. Eur J Endocrinol. 2014;170(2):R75–90. https://doi.org/10.1530/EJE-13-0585; Ceruti JM, Leirós GJ, Balañá ME. Androgens and androgen receptor action in skin and hair follicles. Mol Cell Endocrinol. 2018;465:122–33. https://doi.org/10.1016/j.mce.2017.09.009; Spritzer PM, Marchesan LB, Santos BR, Fighera TM. Hirsutism, Normal androgens and diagnosis of PCOS. Diagnostics (Basel). 2022;12(8):1922. https://doi.org/10.3390/diagnostics12081922; Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006;19(4):210–23. https://doi.org/10.1111/j.1529-8019.2006.00077.x; Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–92. https://doi.org/10.1210/jc.2013-2350; Borzyszkowska D, Niedzielska M, Kozłowski M, Brodowska A, Przepiera A, Malczyk-Matysiak K, et al. Evaluation of hormonal factors in acne vulgaris and the course of acne vulgaris treatment with contraceptive-based therapies in young adult women. Cells. 2022;11(24):4078. https://doi.org/10.3390/cells11244078; Ozdemir S, Ozdemir M, Görkemli H, Kiyici A, Bodur S. Specific dermatologic features of the polycystic ovary syndrome and its association with biochemical markers of the metabolic syndrome and hyperandrogenism. Acta Obstet Gynecol Scand. 2010;89(2):199–204. https://doi.org/10.3109/00016340903353284; Feng JG, Guo Y, Ma LA, Xing J, Sun RF, Zhu W. Prevalence of dermatologic manifestations and metabolic biomarkers in women with polycystic ovary syndrome in north China. J Cosmet Dermatol. 2018;17(3):511–7. https://doi.org/10.1111/jocd.12387; Schmidt TH, Khanijow K, Cedars MI, Huddleston H, Pasch L, Wang ET, et al. Cutaneous findings and systemic associations in women with polycystic ovary syndrome. JAMA Dermatol. 2016;152(4):391–8. https://doi.org/10.1001/jamadermatol.2015.4498; Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab. 2021;106(3):e1071–83. https://doi.org/10.1210/clinem/dgaa839; Amiri M, Kabir A, Nahidi F, Shekofteh M, Ramezani Tehrani F. Effects of combined oral contraceptives on the clinical and biochemical parameters of hyperandrogenism in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Contracept Reprod Health Care. 2018;23(1):64–77. https://doi.org/10.1080/13625187.2018.1435779; Morgante G, Cappelli V, Troìa L, De Leo V. Evaluation of different antiandrogenic progestins on clinical and biochemical variables in polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2020;25(3):176–81. https://doi.org/10.1080/13625187.2020.1736546; De Leo V, Morgante G, Piomboni P, Musacchio MC, Petraglia F, Cianci A. Evaluation of effects of an oral contraceptive containing ethinylestradiol combined with drospirenone on adrenal steroidogenesis in hyperandrogenic women with polycystic ovary syndrome. Fertil Steril. 2007;88(1):113–7. https://doi.org/10.1016/j.fertnstert.2006.11.137; Barrionuevo P, Nabhan M, Altayar O, Wang Z, Erwin PJ, Asi N, et al. Treatment options for hirsutism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2018;103(4):1258–64. https://doi.org/10.1210/jc.2017-02052; Bhattacharya SM, Jha A. Comparative study of the therapeutic effects of oral contraceptive pills containing desogestrel, cyproterone acetate, and drospirenone in patients with polycystic ovary syndrome. Fertil Steril. 2012;98(4):1053–9. https://doi.org/10.1016/j.fertnstert.2012.06.035; Tang Z, Guan J, Mao JH, Han L, Zhang JJ, Chen R, Jiao Z. Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: a model-based meta-analysis. Eur J Pharm Sci. 2023;190:106577. https://doi.org/10.1016/j.ejps.2023.106577; Dorgham N, Sharobim A, Haggag H, El-Kalioby M, Dorgham D. Adding combined oral contraceptives or metformin to laser treatment in polycystic ovarian syndrome hirsute patients. J Drugs Dermatol. 2021;20(3):302–6. https://doi.org/10.36849/JDD.5652; Shobeiri F, Jenabi E. The association between polycystic ovary syndrome and breast cancer: a meta-analysis. Obstet Gynecol Sci. 2016;59(5):367–72. https://doi.org/10.5468/ogs.2016.59.5.367; Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract. 2016;2:14. https://doi.org/10.1186/s40738-016-0029-2; Ding DC, Chen W, Wang JH, Lin SZ. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: a population-based cohort study in Taiwan. Medicine (Baltimore). 2018;97(39):e12608. https://doi.org/10.1097/MD.0000000000012608; Li Z, Wang YH, Wang LL, Hu DT, Teng Y, Zhang TY, et al. Polycystic ovary syndrome and the risk of endometrial, ovarian and breast cancer: an updated meta-analysis. Scott Med J. 2022;67(3):109–20. https://doi.org/10.1177/00369330221107099; Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713–27. https://doi.org/10.1016/s0140-6736(96)90806-5; Mørch LS, Hannaford PC, Lidegaard Ø. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2018;378(13):1265–6. https://doi.org/10.1056/NEJMc1800054; Fitzpatrick D, Pirie K, Reeves G, Green J, Beral V. Combined and progestagen-only hormonal contraceptives and breast cancer risk: a UK nested case–control study and meta-analysis. PLOS Medicine. 2023;20(3):e1004188. https://doi.org/10.1371/journal.pmed.1004188; Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ oral contraception study. Am J Obstet Gynecol. 2017;216(6):580.e1–580.e9. https://doi.org/10.1016/j.ajog.2017.02.002; Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol. 2015;136(1):99–103. https://doi.org/10.1016/j.ygyno.2014.11.012; Dumesic DA, Lobo RA. Cancer risk and PCOS. Steroids. 2013;78(8):782–5. https://doi.org/10.1016/j.steroids.2013.04.004; Indhavivadhana S, Rattanachaiyanont M, Wongwananuruk T, Techatraisak K, Rayasawath N, Dangrat C. Endometrial neoplasia in reproductive-aged Thai women with polycystic ovary syndrome. Int J Gynaecol Obstet. 2018;142(2):170–5. https://doi.org/10.1002/ijgo.12522; Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM; Australian Ovarian Cancer Study Group and Australian National Endometrial Cancer Study Group. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control. 2010;21(12):2303–8. https://doi.org/10.1007/s10552-010-9658-7; Cooney LG, Dokras A. Beyond fertility: polycystic ovary syndrome and long-term health. Fertil Steril. 2018;110(5):794–809. https://doi.org/10.1016/j.fertnstert.2018.08.021; Savaris RF, Groll JM, Young SL, DeMayo FJ, Jeong JW, Hamilton AE, et al. Progesterone resistance in PCOS endometrium: a microarray analysis in clomiphene citrate-treated and artificial menstrual cycles. J Clin Endocrinol Metab. 2011;96(6):1737–46. https://doi.org/10.1210/jc.2010-2600; Li X, Feng Y, Lin JF, Billig H, Shao R. Endometrial progesterone resistance and PCOS. J Biomed Sci. 2014;21(1):2. https://doi.org/10.1186/1423-0127-21-2; Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016;34(35):4225–30. https://doi.org/10.1200/JCO.2016.69.4638; Pérez-Martín AR, Castro-Eguiluz D, Cetina-Pérez L, Velasco-Torres Y, Bahena-González A, Montes-Servín E, et al. Impact of metabolic syndrome on the risk of endometrial cancer and the role of lifestyle in prevention. Bosn J Basic Med Sci. 2022;22(4):499–510. https://doi.org/10.17305/bjbms.2021.6963; Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol. 2018;4(4):516–21. https://doi.org/10.1001/jamaoncol.2017.4942; Burchardt NA, Shafrir AL, Kaaks R, Tworoger SS, Fortner RT. Oral contraceptive use by formulation and endometrial cancer risk among women born in 1947– 1964: The Nurses’ Health Study II, a prospective cohort study. Eur J Epidemiol. 2021;36(8):827–39. https://doi.org/10.1007/s10654-020-00705-5; Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32(5):1075–91. https://doi.org/10.1093/humrep/dex044; Довженко ТВ, Ильина НА, Гродницкая ЕА. Проблема психических нарушений при синдроме поликистозных яичников. Социальная и клиническая психиатрия. 2015;25(2):94–100. EDN: UZQCVP; Edwards AC, Lönn SL, Crump C, Mościcki EK, Sundquist J, Kendler KS, Sundquist K. Oral contraceptive use and risk of suicidal behavior among young women. Psychol Med. 2022;52(9):1710–7. https://doi.org/10.1017/S0033291720003475; Jung SJ, Cho SMJ, Kim HC. Association of oral contraceptive use with suicidal behavior among representative Korean population: results from Korea National Health and Nutrition Examination Survey (2007–2016). J Affect Disord. 2019;243:8–15. https://doi.org/10.1016/j.jad.2018.09.004; Yang Q, Lagerberg T, Sjölander A, Bertone-Johnson ER, Fang F, Ye W, et al. Use of hormonal contraceptives and antidepressants and risks of suicidal behavior and accidents among women with premenstrual disorders: a nationwide cohort study. BMC Med. 2022;20(1):482. https://doi.org/10.1186/s12916-022-02671-z; Dokras A, Sarwer DB, Allison KC, Milman L, Kris-Etherton PM, Kunselman AR, et al. Weight loss and lowering androgens predict improvements in health-related quality of life in women with PCOS. J Clin Endocrinol Metab. 2016;101(8):2966–74. https://doi.org/10.1210/jc.2016-1896; Cinar N, Harmanci A, Demir B, Yildiz BO. Effect of an oral contraceptive on emotional distress, anxiety and depression of women with polycystic ovary syndrome: a prospective study. Hum Reprod. 2012;27(6):1840–5. https://doi.org/10.1093/humrep/des113; Amisi CA. Markers of insulin resistance in polycystic ovary syndrome women: an update. World J Diabetes. 2022;13(3):129–49. https://doi.org/10.4239/wjd.v13.i3.129; Barber TM. Why are women with polycystic ovary syndrome obese? British Medical Bulletin. 2022;143(1):4–15. https://doi.org/10.1093/bmb/ldac007; Guo F, Gong Z, Fernando T, Zhang L, Zhu X, Shi Y. The lipid profiles in different characteristics of women with PCOS and the interaction between dyslipidemia and metabolic disorder states: a retrospective study in Chinese population. Front Endocrinol (Lausanne). 2022;13:892125. https://doi.org/10.3389/fendo.2022.892125; Kazemi M, Pierson RA, Lujan ME, Chilibeck PD, McBreairty LE, Gordon JJ, et al. Comprehensive evaluation of type 2 diabetes and cardiovascular disease risk profiles in reproductive-age women with polycystic ovary syndrome: a large Canadian cohort. J Obstet Gynaecol Can. 2019;41(10):1453–60. https://doi.org/10.1016/j.jogc.2018.11.026; Болотова ЕВ, Дудникова АВ, Крутова ВА, Просолупова НС. Частота и структура метаболических нарушений у женщин с ожирением в сочетании с синдромом поликистозных яичников. Ожирение и метаболизм. 2021;18(3):254–62. https://doi.org/10.14341/omet12374; Kakoly NS, Khomami MB, Joham AE, Cooray SD, Misso ML, Norman RJ, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update. 2018;24(4):455–67. https://doi.org/10.1093/humupd/dmy007; Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020;35:100937. https://doi.org/10.1016/j.molmet.2020.01.001; Li L, Feng Q, Ye M, He Y, Yao A, Shi K. Metabolic effect of obesity on polycystic ovary syndrome in adolescents: a meta-analysis. J Obstet Gynaecol. 2017;37(8):1036–47. https://doi.org/10.1080/01443615.2017.1318840; Behboudi-Gandevani S, Ramezani Tehrani F, Rostami Dovom M, Farahmand M, Bahri Khomami M, Noroozzadeh M, et al. Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies. Gynecol Endocrinol. 2016;32(5):343–53. https://doi.org/10.3109/09513590.2015.1117069; Ollila MM, West S, Keinänen-Kiukaanniemi S, Jokelainen J, Auvinen J, Puukka K, et al. Overweight and obese but not normal weight women with PCOS are at increased risk of type 2 diabetes mellitus—a prospective, population-based cohort study. Hum Reprod. 2017;32(2):423–31. https://doi.org/10.1093/humrep/dew329; Forslund M, Landin-Wilhelmsen K, Trimpou P, Schmidt J, Brännström M, Dahlgren E. Type 2 diabetes mellitus in women with polycystic ovary syndrome during a 24-year period: importance of obesity and abdominal fat distribution. Hum Reprod Open. 2020;(1):hoz042. https://doi.org/10.1093/hropen/hoz042; Kumarendran B, O’Reilly MW, Subramanian A, Šumilo D, Toulis K, Gokhale KM, et al. Polycystic ovary syndrome, combined oral contraceptives, and the risk of dysglycemia: a population-based cohort study with a nested pharmacoepidemiological case-control study. Diabetes Care. 2021;44(12):2758–66. https://doi.org/10.2337/dc21-0437; Wu L, Liu Y, Huang X, Lin K, Liu Y, Li Z, et al. Oral contraceptives (OCs) in combination with metformin versus OCs alone on metabolism in nonobese polycystic ovary syndrome: a meta-analysis and systematic review of randomized controlled trials. Clin Endocrinol (Oxf). 2023;99(1):3–16. https://doi.org/10.1111/cen.14895; Gallo MF, Lopez LM, Grimes DA, Carayon F, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst Rev. 2014;2014(1):CD003987. https://doi.org/10.1002/14651858.CD003987.pub5; Hirschberg AL, Byström B, Carlström K, von Schoultz B. Reduced serum cholecystokinin and increase in body fat during oral contraception. Contraception. 1996;53(2):109–13. https://doi.org/10.1016/0010-7824(95)00265-0; Arusoglu G, Koksal G, Cinar N, Tapan S, Aksoy DY, Yildiz BO. Basal and meal-stimulated ghrelin, PYY, CCK levels and satiety in lean women with polycystic ovary syndrome: effect of low-dose oral contraceptive. J Clin Endocrinol Metab. 2013;98(11):4475–82. https://doi.org/10.1210/jc.2013-1526; Naessén S, Carlström K, Byström B, Pierre Y, Hirschberg AL. Effects of an antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women. Psychoneuroendocrinology. 2007;32(5):548–54. https://doi.org/10.1016/j.psyneuen.2007.03.008; Lindh I, Ellström AA, Milsom I. The long-term influence of combined oral contraceptives on body weight. Hum Reprod. 2011;26(7):1917–24. https://doi.org/10.1093/humrep/der094; Aydin K, Cinar N, Aksoy DY, Bozdag G, Yildiz BO. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception. 2013;87(3):358–62. https://doi.org/10.1016/j.contraception.2012.07.005; Berenson AB, Rahman M. Changes in weight, total fat, percent body fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. Am J Obstet Gynecol. 2009;200(3):329.e1–8. https://doi.org/10.1016/j.ajog.2008.12.052; Pasquali R, Gambineri A, Anconetani B, Vicennati V, Colitta D, Caramelli E, et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf). 1999;50(4):517–27. https://doi.org/10.1046/j.1365-2265.1999.00701.x; Cooney LG, Dokras A. Cardiometabolic risk in polycystic ovary syndrome: current guidelines. Endocrinol Metab Clin North Am. 2021;50(1):83–95. https://doi.org/10.1016/j.ecl.2020.11.001; Беглова АЮ, Елгина СИ. Метаболические и сердечно-сосудистые риски у женщин репродуктивного возраста с синдромом поликистозных яичников. Мать и дитя в Кузбассе. 2018;(4):44–9. EDN: YRNDGH; Amiri M, Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol. 2020;18(1):23. https://doi.org/10.1186/s12958-020-00576-1; Daan NM, Louwers YV, Koster MP, Eijkemans MJ, de Rijke YB, Lentjes EW, et al. Cardiovascular and metabolic profiles amongst different polycystic ovary syndrome phenotypes: who is really at risk? Fertil Steril. 2014;102(5):1444–51.e3. https://doi.org/10.1016/j.fertnstert.2014.08.001; de Medeiros SF. Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome. Reprod Biol Endocrinol. 2017;15(1):93. https://doi.org/10.1186/s12958-017-0313-y; Yildizhan R, Gokce AI, Yildizhan B, Cim N. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up. Gynecol Endocrinol. 2015;31(5):396–400. https://doi.org/10.3109/09513590.2015.1006187; Vieira CS, Martins WP, Fernandes JB, Soares GM, dos Reis RM, de Sá MF, Ferriani RA. The effects of 2 mg chormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. Contraception. 2012;86:268–75. https://doi.org/10.1016/j.contraception.2011.12.011; Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2011;95:1073–9.e1-11. https://doi.org/10.1016/j.fertnstert.2010.12.027; Pinola P, Puukka K, Piltonen TT, Puurunen J, Vanky E, Sundstrom-Poromaa I, et al. Normo- and hyperandrogenic women with polycystic ovary syndrome exhibit an adverse metabolic profile through life. Fertil Steril. 2017;107:788–95.e2. https://doi.org/10.1016/j.fertnstert.2016.12.017; Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459–67. https://doi.org/10.1161/circulationaha.106.628875; Meyer ML, Malek AM, Wild RA, Korytkowski MT, Talbott EO. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(2):112–26. https://doi.org/10.1093/humupd/dmr046; Meun C, Franco OH, Dhana K, Jaspers L, Muka T, Louwers Y, et al. High androgens in postmenopausal women and the risk for atherosclerosis and cardiovascular disease: the Rotterdam Study. J Clin Endocrinol Metab. 2018;103:1622–30. https://doi.org/10.1210/jc.2017-02421; Guan C, Zahid S, Minhas AS, Ouyang P, Vaught A, Baker VL, Michos ED. Polycystic ovary syndrome: a “risk-enhancing” factor for cardiovascular disease. Fertil Steril. 2022;117(5):924–35. https://doi.org/10.1016/j.fertnstert.2022.03.009; Carmina E, Campagna AM, Lobo RA. A 20-year follow-up of young women with polycystic ovary syndrome. Obstet Gynecol. 2012;119(2 Pt 1):263–9. https://doi.org/10.1097/AOG.0b013e31823f7135; Ramezani Tehrani F, Amiri M, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2020;36(1):12–23. https://doi.org/10.1080/09513590.2019.1650337; Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab. 2011;96(12):3794–803. https://doi.org/10.1210/jc.2011-1677; Bajuk Studen K, Pfeifer M. Cardiometabolic risk in polycystic ovary syndrome. Endocr Connect. 2018;7(7):R238–R251. https://doi.org/10.1530/EC-18-0129; Dragoman M, Curtis KM, Gaffield ME. Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes. Contraception. 2016;94(3):280–7. https://doi.org/10.1016/j.contraception.2015.08.002; Gariani K, Hugon-Rodin J, Philippe J, Righini M, Blondon M. Association between polycystic ovary syndrome and venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2020;185:102–8. https://doi.org/10.1016/j.thromres.2019.11.019; Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011;343:d6423. https://doi.org/10.1136/bmj.d6423; Карева ЕН. Тромбозы и гестагены. Доктор.Ру. 2019;(7):57–64. https://doi.org/10.31550/1727-2378-2019-162-7-57-64; Stocco B, Fumagalli HF, Franceschini SA, Martinez EZ, Marzocchi-Machado CM, de Sá MFS, Toloi MRT. Comparative study of the effects of combined oral contraceptives in hemostatic variables: an observational preliminary study. Medicine (Baltimore). 2015;94(4):e385. https://doi.org/10.1097/MD.0000000000000385; Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013;185(2):E115–20. https://doi.org/10.1503/cmaj.120677; Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL. Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003– 2008. Am J Obstet Gynecol. 2012;207(5):377.e1–8. https://doi.org/10.1016/j.ajog.2012.08.007; Girum T, Wasie A. Return of fertility after discontinuation of contraception: a systematic review and meta-analysis. Contracept Reprod Med. 2018;3:9. https://doi.org/10.1186/s40834-018-0064-y; Landersoe SK, Petersen KB, Vassard D, Larsen EC, Nielsen HS, Pinborg A, et al. Concerns on future fertility among users and past-users of combined oral contraceptives: a questionnaire survey. Eur J Contracept Reprod Health Care. 2019;24(5):347–55. https://doi.org/10.1080/13625187.2019.1639659; Yland JJ, Bresnick KA, Hatch EE, Wesselink AK, Mikkelsen EM, Rothman KJ, et al. Pregravid contraceptive use and fecundability: prospective cohort study. BMJ. 2020;371:m3966. https://doi.org/10.1136/bmj.m3966; Siegel DR, Fresia J, Fought A, Sheeder J, Hampanda K, Appiah L. The effect of hormonal contraception use on ovarian reserve markers and the uptake of assisted reproductive technology in individuals seeking an infertility evaluation. Cureus. 2023;15(6):e40927. https://doi.org/10.7759/cureus.40927; Song SY, Yang JB, Song MS, Oh HY, Lee GW, Lee M, et al. Effect of pretreatment with combined oral contraceptives on outcomes of assisted reproductive technology for women with polycystic ovary syndrome: a meta-analysis. Arch Gynecol Obstet. 2019;300(3):737–50. https://doi.org/10.1007/s00404-019-05210-z; https://www.risksafety.ru/jour/article/view/426
-
4Academic Journal
Authors: A. D. Makatsariya, V. O. Bitsadze, A. G. Solopova, O. A. Gromova, D. I. Korabelnikov, D. V. Blinov, J. Kh. Khizroeva, N. A. Makatsariya, M. V. Tretyakova, S. A. Akavova, D. M. Ampilogova, А. Д. Макацария, В. О. Бицадзе, А. Г. Солопова, О. А. Громова, Д. И. Корабельников, Д. В. Блинов, Д. Х. Хизроева, Н. А. Макацария, М. В. Третьякова, С. А. Акавова, Д. М. Ампилогова
Contributors: The work was financially supported by Sanofi pharmaceutical company, Работа выполнена при финансовой поддержке фармацевтической компании Санофи
Source: Obstetrics, Gynecology and Reproduction; Vol 18, No 2 (2024); 218-230 ; Акушерство, Гинекология и Репродукция; Vol 18, No 2 (2024); 218-230 ; 2500-3194 ; 2313-7347
Subject Terms: витамин B 6, magnesium deficiency, dysmenorrhea, premenstrual syndrome, PMS, polycystic ovarian syndrome, POS, menopause, climacteric syndrome, osteoporosis, oral combined oral contraceptives, COCs, menopausal hormone therapy, MHT, magnesium citrate, pyridoxine, vitamin B 6, дефицит магния, дисменорея, предменструальный синдром, ПМС, синдром поликистозных яичников, СПКЯ, климакс, климактерический синдром, остеопороз, комбинированные оральные контрацептивы, КОК, менопаузальная гормональная терапия, МГТ
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/2053/1202; Grober U., Schmidt J., Kisters K. Magnesium in prevention and therapy. Nutrients. 2015;7(9):8199–226. doi:10.3390/nu7095388.; Bertinato J., Wu Xiao C., Ratnayake W.M. et al. Lower serum magnesium concentration is associated with diabetes, insulin resistance, and obesity in South Asian and white Canadian women but not men. Food Nutr Res. 2015;59(1):25974. doi:10.3402/fnr.v59.25974.; Al Alawi M.A., Majoni S.W., Falhammar H. Magnesium and human health: perspectives and research directions. Int J Endocrinol. 2018;2018:9041694. doi:10.1155/2018/9041694.; Громова О.А., Торшин И.Ю., Рудаков К.В. и др. Недостаточность магния – достоверный фактор риска коморбидных состояний: результаты крупномасштабного скрининга магниевого статуса в регионах России. Фарматека. 2013;(6):115–29.; Блинов Д.В., Ушакова Т.И., Макацария Н.А. и др. Гормональная контрацепция и дефицит магния: результаты субанализа исследования MAGYN. Акушерство, Гинекология и Репродукция. 2017;11(1):36–48. doi:10.17749/2313-7347.2017.11.1.036-048.; Блинов Д.В., Зимовина У.В., Джобава Э.М. Ведение беременных с дефицитом магния: фармакоэпидемиологическое исследование. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2014;7(2):23–32.; Makatsariya A.D., Bitsadze V.O, Blinov D.V. et al. Pregnant women with symptoms of magnesium deficiency in Russian Federation: MAGIC 2 study results. Magnes Res. 2016;29(3):81. URL: https://www.researchgate.net/publication/316007448_Pregnant_women_with_symptoms_of_magnesium_deficiency_in_Russian_Federation_MAGIC_2_study_results.; Блинов Д.В., Зимовина У.В., Сандакова Е.А., Ушакова Т.И. Дефицит магния у пациенток с гормонально-зависимыми заболеваниями: фармакоэпидемиологический профиль и оценка качества жизни. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2015;8(2):16–24. URL: https://cyberleninka.ru/article/n/defitsit-magniya-u-patsientok-s-gormonalno-zavisimymi-zabolevaniyami-farmakoepidemiologicheskiy-profil-i-otsenka-kachestva-zhizni.; Schimatschek H.F., Rempis R. Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res. 2001;14(4):283–90.; De Baaij J.H.F., Hoenderop J.G.J., Bindels R.J.M. Magnesium in man: implications for health and disease. Physiol Rev. 2015;95(1):1–46. doi:10.1152/physrev.00012.2014.; Olza J., Aranceta-Bartrina J., González-Gross M. et al. Reported dietary intake, disparity between the reported consumption and the level needed for adequacy and food sources of calcium, phosphorus, magnesium and vitamin D in the Spanish population: findings from the ANIBES study. Nutrients. 2017;9(2):168. doi:10.3390/nu9020168.; Olza J., Aranceta-Bartrina J., González-Gross M. et al. Reported dietary intake and food sources of zinc, selenium, and vitamins A, E and C in the Spanish population: findings from the ANIBES study. Nutrients. 2017;9(7):697. doi:10.3390/nu9070697.; Jahnen-Dechent W., Ketteler M. Magnesium basics. Clin Kidney J. 2012;5(Suppl 1):i3–i14. doi:10.1093/ndtplus/sfr163.; Danziger J., William J.H., Scott D.J. et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int. 2013;83(4):692–9. doi:10.1038/ki.2012.452.; Наумов Д.Е. Термочувствительные ионные каналы TRPM8 (oбзор литературы). Бюллетень физиологии и патологии дыхания. 2011;(42):89–96.; Громова О.А., Гоголева И.В. Применение магния в зеркале доказательной медицины и фундаментальных исследований в терапии. Дефицит магния и концепция стресса. Трудный пациент. 2007;5(11):29–38.; Voets T., Nilius B., Hoefs S. et al. TRPM6 Forms the Mg 2+ influx channel involved in intestinal and renal Mg 2+ absorption. J Biol Chem. 2004;279(1):19–25. doi:10.1074/jbc.M311201200.; Schlingmann K.P., Gudermann T. A critical role of TRPM channel-kinase for human magnesium transport. J Physiol. 2005;566(Pt 2):301–8. doi:10.1113/jphysiol.2004.080200.; Pilchova I., Klacanova K., Tatarkova Z. et al. The involvement of Mg 2+ in regulation of cellular and mitochondrial functions. Oxid Med Cell Longev. 2017;2017:6797460. doi:10.1155/2017/6797460.; Sontia B., Touyz R.M. Magnesium transport in hypertension. Pathophysiology. 2007;14(3–4):205–11. doi:10.1016/j.pathophys.2007.09.005.; Mutnuri S., Fernandez I., Kochar T. Suppression of parathyroid hormone in a patient with severe magnesium depletion. Case Rep Nephrol. 2016;2016:2608538. doi:10.1155/2016/2608538.; Viering D.H.H.M., de Baaij J.H.F., Walsh S.B. et al. Genetic causes of hypomagnesemia, a clinical overview. Pediatr Nephrol. 2017;32(7):1123–35. doi:10.1007/s00467-016-3416-3.; Seo J.W., Park T.J. Magnesium metabolism. Electrolyte Blood Press. 2008;6(2):86–95. doi:10.5049/EBP.2008.6.2.86.; Pham P.C.T., Pham P.-A.T., Pham S.V. et al. Hypomagnesemia: a clinical perspective. Int J Nephrol Renovasc Dis. 2014;7:219–30. doi:10.2147/IJNRD.S42054.; Lajer H., Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev. 1999;25(1):47–58. doi:10.1053/ctrv.1999.0097.; Bagnis C.I., Deray G. Amphotericin B nephrotoxicity. Saudi J Kidney Dis Transpl. 2002;13(4):481–91.; Lee C.H., Kim G.-H. Electrolyte and acid-base disturbances induced by clacineurin inhibitors. Electrolyte Blood Press. 2007;5(2):126–30. doi:10.5049/EBP.2007.5.2.126.; Sivakumar J. Proton pump inhibitor-induced hypomagnesaemia and hypocalcaemia : case review. Int J Physiol Pathophysiol Pharmacol. 2016;8(4):169–74.; Atsmon J., Dolev E. Drug-induced hypomagnesaemia: scope and management. Drug Saf. 2005;28(9):763–88. doi:10.2165/00002018-200528090-00003.; Makatsariya A.D., Dzhobava E.M., Bitsadze V.O. et al. Observational study of outpatient women in hormone dependent conditions with magnesium deficiency and receiving Magne B6® Forte in Russia (MAGYN Study). Magnes Res. 2016;29(3):82. URL: https://www.researchgate.net/publication/316007423_Observational_study_of_outpatient_women_in_hormone_dependent_conditions_with_magnesium_deficiency_and_receiving_Magne_B6_Forte_in_Russia_MAGYN_Study.; Ryu A., Kim T.H. Premenstrual syndrome : a mini review. Maturitas. 2015;82(4):436–40. doi:10.1016/j.maturitas.2015.08.010.; Rosenstein D.L., Elin R.J., Hosseini J.M. et al. Magnesium measures across the menstrual cycle in premenstrual syndrome. Biol Psychiatry. 1994;35(8):557–61. doi:10.1016/0006-3223(94)90103-1.; Sherwood R.A., Rocks B.F., Stewart A., Saxton R.S. Magnesium and the premenstrual syndrome. Ann Clin Biochem. 1986;23(Pt 6):667–70. doi:10.1177/000456328602300607.; Muneyyirci-Delale O., Nacharaju V.L., Altura B.M., Altura B.T. Sex steroid hormones modulate serum ionized magnesium and calcium levels throughout the menstrual cycle in women. Fertil Steril. 1998;69(5):958–2. doi:10.1016/S0015-0282(98)00053-3.; Tonick S., Muneyyirci-Delale O. Magnesium in women’s health and gynecology. Open J Obstet Gynecol. 2016;6(5):325–33. doi:10.4236/ojog.2016.65041.; Facchinetti F., Sances G., Borella P. et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache. 1991;31(5):298–301. doi:10.1111/j.1526-4610.1991.hed3105298.x.; Walker A.F., De Souza M.C., Vickers M.F. et al. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health. 1998;7(9):1157–65. doi:10.1089/jwh.1998.7.1157.; Quaranta S., Buscaglia M.A., Meroni M.G. et al. Pilot study of the efficacy and safety of a modified-release magnesium 250 mg tablet (Sincromag) for the treatment of premenstrual syndrome. Clin Drug Investig. 2007;27(1):51–8. doi:10.2165/00044011-200727010-00004.; De Souza M.C., Walker A.F., Robinson P.A., Bolland K. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med. 2000;9(2):131–9. doi:10.1089/152460900318623.; Fathizadeh N., Ebrahimi E., Valiani M. et al. Evaluating the effect of magnesium and magnesium plus vitamin B6 supplement on the severity of premenstrual syndrome. Iran J Nurs Midwifery Res. 2010;15(Suppl 1):401–5.; Дадак К., Макацария А.Д., Блинов Д.В., Зимовина У.В. Клинические и биохимические аспекты применения препаратов магния в акушерстве, гинекологии и перинатологии. Акушерство, Гинекология и Репродукция. 2014;8(2):69–78.; Черкасова Н.Ю., Фомина А.В., Филиппова О.В. Анализ рынка лекарственных средств для лечения дисменореи. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2013;6(3):36–9.; Унанян А.Л., Алимов В.А., Аракелов С.Э. и др. Фармакоэпидемиология использования оригинального дротаверина при дисменорее: результаты международного многоцентрового исследования. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2014;7(3):44–50.; Оразов М.Р., Чайка А.В., Носенко Е.Н. Купирование хронической тазовой боли, обусловленной аденомиозом, прогестагенами нового поколения. Акушерство, Гинекология и Репродукция. 2014;8(3):6–10.; Джобава Э.М. Вопросы безопасности применения дротаверина в акушерской практике. Акушерство, Гинекология и Репродукция. 2018;12(1):54–60. doi:10.17749/2313-7347.2018.12.1.054-060.; Proctor M.L., Farquhar C.M. Dysmenorrhoea. BMJ Clin Evid. 2007;2007:0813.; Proctor M., Murphy P. A. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2001;(3):CD002124. doi:10.1002/14651858.CD002124.; Seifert B., Wagler P., Dartsch S. et al. Magnesium – a new therapeutic alternative in primary dysmenorrhea. Zentralbl Gynakol. 1989;111(11):755–60. (In German).; Parazzini F., Di Martino M., Pellegrino P. Magnesium in the gynecological practice : a literature review. Magnes Res. 2017;30(1):1–7. doi:10.1684/mrh.2017.0419.; Fontana-Klaiber H., Hogg B. Therapeutic effects of magnesium in dysmenorrhea. Schweiz Rundsch Med Prax. 1990;79(16):491–4. (In German).; Benassi L., Barletta F.P., Baroncini L. et al. Effectiveness of magnesium pidolate in the prophylactic treatment of primary dysmenorrhea. Clin Exp Obstet Gynecol. 1992;19(3):176–9.; Higdon J. An evidence-based approach to vitamins and minerals: health benefits and intake recommendations. Stuttgart, New York: Thieme, 2012. 282 p.; Olatunji L.A., Oyeyipo I.P., Micheal O.S., Soladoye A.O. Effect of dietary magnesium on glucose tolerance and plasma lipid during oral contraceptive administration in female rats. Afr J Med Med Sci. 2008;37(2):135–9.; Akinloye O., Adebayo T.O., Oguntibeju O.O. et al. Effects of contraceptives on serum trace elements, calcium and phosphorus levels. West Indian Med J. 2011;60(3):308–15.; Muneyyirci-Delale O., Nacharaju V.L., Dalloul M. et al. Divalent cations in women with PCOS: implications for cardiovascular disease. Gynecol Endocrinol. 2001;15(3):198–201. doi:10.1080/gye.15.3.198.201.; Sharifi F., Mazloomi S., Hajihosseini R. et al. Serum magnesium concentrations in polycystic ovary syndrome and its association with insulin resistance. Gynecol Endocrinol. 2012;28(1):7–11. doi:10.3109/09513590.2011.579663.; O’Shaughnessy A., Muneyyirci-Delale O., Nacharaju V.L. et al. Circulating divalent cations in asymptomatic ovarian hyperstimulation and in vitro fertilization patients. Gynecol Obstet Invest. 2001;52(4):237–42. doi:10.1159/000052982.; Bird S.T., Hartzema A.G., Brophy J.M. et al. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ. 2013;185(2):E115–20. doi:10.1503/cmaj.120677.; Громова О.А., Лиманова О.А., Торшин И.Ю. Систематический анализ фундаментальных и клинических исследований указывает на необходимость совместного использования эстроген-содержащих препаратов с препаратами пиридоксина и магния. Акушерство, Гинекология и Репродукция. 2013;7(3):35–50.; Farsinejad-Marj M., Saneei P., Esmaillzadeh A. Dietary magnesium intake, bone mineral density and risk of fracture : a systematic review and meta-analysis. Osteoporos Int. 2016;27(4):1389–99. doi:10.1007/s00198-015-3400-y.; Gur A., Colpan L., Nas K. et al. The role of trace minerals in the pathogenesis of postmenopausal osteoporosis and a new effect of calcitonin. J Bone Miner Metab. 2002;20(1):39–43. doi:10.1007/s774-002-8445-y.; Brodowski J. Levels of ionized magnesium in women with various stages of postmenopausal osteoporosis progression evaluated on the basis of densitometric examinations. Przegl Lek. 2000;57(12):714–6. (In Polish).; Дефицит магния в акушерстве и гинекологии: результаты национального совещания. Акушерство, Гинекология и Репродукция. 2014;8(2):6–10.; Солопова А.Г., Блинов Д.В., Бегович Ё. и др. Неврологические расстройства после гистерэктомии: от патогенеза к клинике. Эпилепсия и пароксизмальные состояния. 2022;14(1):54–64. doi:10.17749/2077-8333/epi.par.con.2022.115.; Блинов Д.В., Солопова А.Г., Плутницкий А.Н. и др. Организация здравоохранения в сфере реабилитации пациенток с онкологическими заболеваниями репродуктивной системы. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2022;15(1):119–30. URL: https://cyberleninka.ru/article/n/organizatsiya-zdravoohraneniya-v-sfere-reabilitatsii-patsientok-s-onkologicheskimi-zabolevaniyami-reproduktivnoy-sistemy.; Блинов Д.В., Солопова А.Г., Ачкасов Е.Е. и др. Медицинская реабилитация пациенток с климактерическим синдромом и хирургической менопаузой: вклад коррекции дефицита магния. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2022;15(4):478–90. doi:10.17749/2070-4909/farmakoekonomika.2022.159.; Блинов Д.В., Солопова А.Г., Ачкасов Е.Е. и др. Роль коррекции дефицита магния в реабилитации женщин с климактерическим синдромом и хирургической менопаузой: результаты исследования MAGYN. Акушерство, Гинекология и Репродукция. 2022;16(6):676–91. doi:10.17749/2313-7347/ob.gyn.rep.2022.371.; Блинов Д.В., Солопова А.Г., Ачкасов Е.Е. и др. Организация реабилитации пациенток с опухолями яичников: современные подходы и будущие направления. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2023;16(2):303–16. URL: https://www.elibrary.ru/ip_restricted.asp?rpage=https%3A%2F%2Fwww%2Eelibrary%2Eru%2Fitem%2Easp%3Fedn%3Ddcaony.; Блинов Д.В., Солопова А.Г., Ачкасов Е.Е. и др. Алгоритм комплексной психотерапевтической поддержки для женщин с психоневрологическими симптомами в период реабилитации после лечения злокачественных новообразований репродуктивной системы. Эпилепсия и пароксизмальные состояния. 2023;15(3):232–45. doi:10.17749/2077-8333/epi.par.con.2023.168.; Магне B6. Инструкция по медицинскому применению. ЛСР-007053/09. Режим доступа: http://www.grls.rosminzdrav.ru. [Дата доступа: 13. 01. 2024].; Магне B6 Форте. Инструкция по медицинскому применению. ЛСР-007053/09. Режим доступа: http://www.grls.rosminzdrav.ru]. [Дата доступа: 13. 01. 2024].; Дижевская Е.В. Мультидисциплинарный подход к коррекции магний-дефицитных состояний. Акушерство, Гинекология и Репродукция. 2015;9(3):68–85.; Дижевская Е.В. Обмен научными данными и экспертными мнениями по фармакотерапии в течение беременности: традиционные и современные подходы III Международный экспертный совет по проблемам дефицита магния в акушерстве и гинекологии. Акушерство, Гинекология и Репродукция. 2015;9(4):93–101.; О Пленуме Президиума Российского общества акушеров-гинекологов. Акушерство и гинекология. 2015;(5):113–5.; Громова О.А. Дефицит магния как проблема современного питания у детей и подростков. Педиатрическая фармакология. 2014;(1):20–30.; Ranade V.V., Somberg J.C. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther. 2001;8(5):345–57. doi:10.1097/00045391-200109000-00008.; https://www.gynecology.su/jour/article/view/2053
-
5Academic Journal
Authors: Rykova, O.V.
Source: Mìžnarodnij Endokrinologìčnij Žurnal, Vol 14, Iss 7, Pp 673-676 (2018)
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY; Том 14, № 7 (2018); 673-676
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 14, № 7 (2018); 673-676
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 14, № 7 (2018); 673-676Subject Terms: thyroid gland, комбинированные оральные контрацептивы, синдром поликистозных яичников, щитовидная железа, гиперпролактинемия, врожденная дисфункция коры надпочечников, синдром Кушинга, акромегалия, RC648-665, Diseases of the endocrine glands. Clinical endocrinology, 3. Good health, комбіновані оральні контрацептиви, синдром полікістозних яєчників, щитоподібна залоза, гіперпролактинемія, уроджена дисфункція кори надниркових залоз, акромегалія, 03 medical and health sciences, 0302 clinical medicine, combined oral contraceptives, polycystic ovarian syndrome, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, acromegaly
File Description: application/pdf
-
6Academic Journal
Source: Репродуктивное здоровье. Восточная Европа. :286-295
Subject Terms: hyperandrogenism, 03 medical and health sciences, puberty, 0302 clinical medicine, гиперандрогения, polycystic ovary syndrome, combined oral contraceptives, пубертатный период, синдром поликистозных яичников, комбинированные оральные контрацептивы, 3. Good health
-
7Academic Journal
Source: Сборник статей
Subject Terms: REPRODUCTIVE HEALTH, COMBINED ORAL CONTRACEPTIVES, CHANGE OF BODY MASS, РЕПРОДУКТИВНОЕ ЗДОРОВЬЕ, КОМБИНИРОВАННЫЕ ОРАЛЬНЫЕ КОНТРАЦЕПТИВЫ, ИЗМЕНЕНИЕ МАССЫ ТЕЛА
File Description: application/pdf
Relation: Актуальные вопросы современной медицинской науки и здравоохранения: материалы VII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 17-18 мая 2022 г.; http://elib.usma.ru/handle/usma/7382
Availability: http://elib.usma.ru/handle/usma/7382
-
8Academic Journal
Authors: Yagubova, G. Kh., Kuyanova, K. S., Kudryavtseva, E. V., Ягубова, Г. Х., Куянова, К. С., Кудрявцева, Е. В.
Source: Сборник статей
Subject Terms: OBESITY, ORAL CONTRACEPTIVES, CONTRACEPTION, BODY MASS INDEX, ОЖИРЕНИЕ, ОРАЛЬНЫЕ КОНТРАЦЕПТИВЫ, КОНТРАЦЕПЦИЯ, ИНДЕКС МАССЫ ТЕЛА
File Description: application/pdf
Relation: Актуальные вопросы современной медицинской науки и здравоохранения: материалы VII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 17-18 мая 2022 г.; http://elib.usma.ru/handle/usma/7421
Availability: http://elib.usma.ru/handle/usma/7421
-
9Academic Journal
Authors: G. B. Dikke, Г. Б. Дикке
Source: Obstetrics, Gynecology and Reproduction; Vol 16, No 3 (2022); 244-254 ; Акушерство, Гинекология и Репродукция; Vol 16, No 3 (2022); 244-254 ; 2500-3194 ; 2313-7347
Subject Terms: ДЗГ, side effects, breakthrough bleeding, three-phase combined oral contraceptives, COCs, desogestrel, DSG, побочные эффекты, прорывные кровотечения, трехфазные комбинированные оральные контрацептивы, КОК, дезогестрел
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/1349/1020; Schindler A.E., Campagnoli C., Druckmann R. et al. Classification and pharmacology of progestins. Maturitas. 2008;61(1):171–80. https://doi.org/10.1016/j.maturitas.2003.09.014.; Kulier R., Helmerhorst F.M., Maitra N., Gülmezoglu A.M. Effectiveness and acceptability of progestogens in combined oral contraceptives – a systematic review. Reprod Health. 2004;1(1):1–9. https://doi.org/10.1186/1742-4755-1-1.; Hooper D.J. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, selfadministered, online survey. Clin Drug Investig. 2010;30(11):749–63. https://doi.org/10.2165/11538900-000000000-00000.; Прилепская В.Н., Назарова Н.М., Тарасова М.А., Летуновская А.Б. Международный проект «CHOICE»: краткий обзор результатов исследования. Гинекология. 2010;12(4):26–8.; Жук С.И., Захурдаева Л.Д. Особенности современного консультирования по вопросам контрацепции. Медицинские аспекты здоровья женщины. 2011;(4):29–32.; Moreau C., Cleland K., Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007;76(4):267–72. https://doi.org/10.1016/j.contraception.2007.06.008.; Fait T., Buryak D., Cirstoiu M.-M. et al. Needs and preferences of women users of oral contraceptives in selected countries in Central and Eastern Europe. Drugs Context. 2018;7:212510. https://doi.org/10.7573/dic.212510.; Bahamondes L., Pinho F., de Melo N.R. et al. Associated factors with discontinuation use of combined oral contraceptives. Rev Bras Ginecol Obstet. 2011;33(6):303–9. [Article in Portuguese]. https://doi.org/10.1590/s0100-72032011000600007.; Пустотина О.А., Герейбекова Э.Р. Побочные эффекты современных комбинированных оральных контрацептивов. Акушерство и гинекология. Новости. Мнения. Обучение. 2016;(3):96–102.; Мынко О.И., Ашрафзянова Д.Р., Лобанова В.В. Комбинированные оральные контрацептивы: частота применения и возникновения побочных эффектов у женщин репродуктивного возраста. ЭНИГМА. 2020;(26):105–14.; Mack N., Crawford T.J., Guise J.M. et al. Strategies to improve adherence and continuation of shorter-term hormonal methods of contraception. Cochrane Database Syst Rev. 2019;4(4):CD004317. https://doi.org/10.1002/14651858.CD004317.pub5.; Poindexter A. The emerging use of the 20-microg oral contraceptive. Fertil Steril. 2001;75(3):457–6. https://doi.org/10.1016/s0015-0282(00)01747-7.; Edelman A., Micks E., Gallo M.F. et al. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014;2014(7):CD004695. https://doi.org/10.1002/14651858.CD004695.pub3.; Gallo M.F., Nanda K., Grimes D.A. et al. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;2013(8):CD003989. https://doi.org/10.1002/14651858.CD003989.pub5.; Carr B.R. Cycle control with desogestrel-containing oral contraceptives comparison of a monophasic and triphasic regimen. Int J Fertil Menopausal Stud. 1993;38(5):274–9.; Darney P. Safety and efficacy of a triphasic oral contraceptive containing desogestrel: results of three multicenter trials. Contraception. 1993;48(4):323–37. https://doi.org/10.1016/0010-7824(93)90078-l.; Ferguson H., Vree M.L., Wilpshaar J., Eskes T.K. Multicenter study of the efficacy, cycle control and tolerability of a phasic desogestrel-containing oral contraceptive. Eur J Contracept Reprod Health Care. 2000;5(1):35– 45. https://doi.org/10.1080/13625180008500378.; Coenen C.M., Thomas C.M., Borm G.F. et al. Changes in androgens during treatment with four low-dose contraceptives. Contraception. 1996;53(3):171–6. https://doi.org/10.1016/0010-7824(96)00006-6.; Katz H.I., Kempers S., Akin M.D. et al. Effect of a desogestrel-containing oral contraceptive on the skin. Eur J ContraceptReprod Health Care. 2000;5(4):248–55. https://doi.org/10.1080/13625180008500411.; Prilepskaya V.N., Serov V.N., Zharov E.V. et al. Effects of a phasic oral contraceptive containing desogestrel on facial seborrhea and acne. Contraception. 2003;68(4):239–45. https://doi.org/10.1016/s0010-7824(03)00167-7.; Kränzlin H.T., Nap M.A. The effect of a phasic oral contraceptive containing Desogestrel on seborrhea and acne. Eur J Contracept Reprod Health Care. 2006;11(1):6–13. https://doi.org/10.1080/13625180500252638.; Vartiainen M., de Gezelle H., Broekmeulen C.J. Comparison of the effect on acne with a combiphasicdesogestrel-containing oral contraceptive and a preparation containing cyproterone acetate. Eur J Contracept Reprod Health Care. 2001;6(1):46–53.; van Vloten W.A., van Haselen C.W., van Zuuren E.J. et al. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(4 Suppl):2–15.; De Leo V., Di Sabatino A., Musacchio M.C. et al. Effect of oral contraceptives on markers of hyperandrogenism and SHBG in women with polycystic ovary syndrome. Contraception. 2010;82(3):276–80. https://doi.org/10.1016/j.contraception.2010.04.002.; van Vliet H.A., Grimes D.A., Lopez L.M. et al. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2011; 2011(11):CD003553. https://doi.org/10.1002/14651858.CD003553.pub2.; American College of Obstetricians and Gynecologists’ Committee on Health Care for Underserved Women, Contraceptive Equity Expert Work Group, and Committee on Ethic. Patient-Centered Contraceptive Counseling. ACOG Committee Statement Number 1. Obstet Gynecol. 2022;139(2):350–3. https://doi.org/10.1097/AOG.0000000000004659.; Dinger J., Bardenheuer K., Heinemann K. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception. 2014;89(4):253–63. https://doi.org/10.1016/j.contraception.2014.01.023.; Kashanian M., Shahpourian F., Zare O. A comparison between monophasic levonorgestrel-ethinyl estradiol 150/30 and triphasic levonorgestrel-ethinyl estradiol 50-75-125/30-40-30 contraceptive pills for side effects and patient satisfaction: a study in Iran. Eur J Obstet Gynecol Reprod Biol. 2010;150(1):47–51. https://doi.org/10.1016/j.ejogrb.2010.01.010.; Roumen F.J. Review of the combined contraceptive vaginal ring, NuvaRing. Ther Clin Risk Manag. 2008;4(2):441–51. https://doi.org/10.2147/tcrm.s1964.; Lawrie T.A., Helmerhorst F.M., Maitra N.K. et al. Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev. 2011;(5):CD004861. https://doi.org/10.1002/14651858.CD004861.pub2.; Grossman BN. Managing adverse effects of hormonal contraceptives. Am Fam Physician. 2010;82(12):1499–506.; Foran T. The management of irregular bleeding in women using contraception. Aust Fam Physician. 2017;46(10):717–20.; Oral contraceptive-related uterine bleeding management. Family Practice Notebook. Available at: https://fpnotebook.com/Gyn/Pharm/OrlCntrcptvRltdUtrnBldngMngmnt.htm.; Vree M.L., Schmidt J. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany. Eur J Contracept Reprod Health Care. 2001;6(2):108–14.; Дикке Г.Б. Пять шагов к успешной контрацепции. Руководство для врачей. М., 2017. 428 с.; Кузнецова И.В. Метаболические эффекты комбинированной гормональной контрацепции и риск тромботических осложнений. Акушерство и гинекология. 2016;(6):108–14. https://doi.org/10.18565/aig.2016.6.108-114.; Baerwald A.R., Pierson R.A. Ovarian follicular development during the use of oral contraception: a review. J Obstet Gynaecol Can. 2004;26(1):19–24. https://doi.org/10.1016/s1701-2163(16)30692-2/; Bastianelli C., Farris M., Rosato E. et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 1. Effects on metabolism. Expert Rev Clin Pharmacol. 2017;10(3):315–26. https://doi.org/10.1080/17512433.2017.1271708.; Lobo R.A., Skinner J.B., Lippman J.S., Cirillo S.J. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertil Steril. 1996;65(6):1100–9.; Silva-Bermudez L.S., Toloza F.J.K., Perez-Matos M.C. et al. Effects of oral contraceptives on metabolic parameters in adult premenopausal women: a meta-analysis. Endocr Connect. 2020;9(10):978–98. https://doi.org/10.1530/EC-20-0423.; Godsland I.F., Walton C., Felton C. et al. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab. 1992;74(1):6470. https://doi.org/10.1210/jcem.74.1.1530790.; Gaspard U., Endrikat J., Desager J.P. et al. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception. 2004;69(4):271–8. https://doi.org/10.1016/j.contraception.2003.11.003.; Adeyanju O.A., Olatunji L.A. Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone. J Bas Clinic Physiol Pharm. 2019;30(5):20180184. https://doi.org/10.1515/jbcpp-2018-0184.; Радзинский В.Е., Хамошина М.Б., Абдуллаева Р.Г., Лебедева М.Г. Гормональная контрацепция – лечение и профилактика репродуктивных нарушений у девушек-подростков. Доктор.Ру. 2008;(6):54–8.; https://www.gynecology.su/jour/article/view/1349
-
10Academic Journal
Authors: Dikke G.B.
Source: Медицинский совет, Vol 0, Iss 13, Pp 40-44 (2018)
Медицинский советSubject Terms: неконтрацептивные эффекты, фолаты, homocysteine, комбинированные оральные контрацептивы, folate, 3. Good health, протективное действие, 03 medical and health sciences, non-contraceptive effects, 0302 clinical medicine, protective effect, combined oral contraceptives, syndrome of polycystic ovaries, левомефолат кальция, гомоцистеин, Medicine, синдром поликистозных яичников, calcium levomefolate, дроспиренон, drospirenone
Access URL: https://doaj.org/article/be4526f9102a47219f565c83c4627b8f
https://openrepository.ru/article?id=245727
https://www.med-sovet.pro/jour/article/download/2600/2564
https://www.med-sovet.pro/jour/article/view/2600
https://cyberleninka.ru/article/n/terapevticheskaya-taktika-pri-narusheniyah-menstrualnogo-tsikla-vyzvannyh-ovulyatornoy-disfunktsiey
https://cyberleninka.ru/article/n/terapevticheskaya-taktika-pri-narusheniyah-menstrualnogo-tsikla-vyzvannyh-ovulyatornoy-disfunktsiey/pdf -
11Academic Journal
Authors: Толстанова, Г.О.
Source: Reproductive health of woman; No. 7-8 (2021); 66-70 ; Reproductive health of woman; № 7-8 (2021); 66-70 ; Репродуктивне здоров'я жінки; № 7-8 (2021); 66-70 ; 2708-8731 ; 2708-8723
Subject Terms: uterine fibroids, conservative myomectomy, fibroid recurrence, myomatous node, progestogens, norethisterone, oral contraceptives, миома матки, консервативная миомэктомия, рецидив миомы, миоматозный узел, прогестагены, норэтистерон, оральные контрацептивы, міома матки, консервативна міомектомія, рецидив міоми, міоматозний вузол, прогестагени, норетистерон, оральні контрацептиви
File Description: application/pdf
-
12Academic Journal
Authors: O. A. Limanova, O. A. Gromova, L. E. Fedotova, О. . А Лиманова, О. А. Громова, Л. Э. Федотова
Source: Pharmacokinetics and Pharmacodynamics; № 3 (2020); 30-39 ; Фармакокинетика и Фармакодинамика; № 3 (2020); 30-39 ; 2686-8830 ; 2587-7836
Subject Terms: фармакодинамическое и фармакокинетическое взаимодействие, combined oral contraceptives, antiviral, antibacterial, anti-inflammatory, antithrombotic, antimigrenous, antihypertensive, oral hypoglycemic, medicinal products, essential micronutrients, pharmacodynamic and pharmacokinetic interaction, комбинированные оральные контрацептивы, противовирусные, антибактери-альные, противовоспалительные, антитромботические, антимигренозные, антигипертензивные, пероральные сахароснижаюшие, лекарственные средства (ЛС), эссенциальные микронутриенты
File Description: application/pdf
Relation: https://www.pharmacokinetica.ru/jour/article/view/255/250; WHO. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance. 13 March 2020. Accessed April 20, 2020. Available at: https://www.who.int/publicationsdetail/clinical-management-of-severe-acuterespiratory-infection-whennovel-coronavirus-(ncov)-infection-issuspected; Jin JM, Bai P, He W et al. Gender Differences in Patients with COVID-19: Focus on Severity and Mortality. Front Public Health. 2020;8:152. DOI:10.3389/fpubh.2020.00152; Адамян Л.В., Азнаурова Я.Б., Филиппов О.С. COVID-19 и женское здоровье (обзор литературы) // Проблемы репродукции. 2020;26(2):6-17.; Министерство здравоохранения Российской Федерации. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 9 (26.10.2020).; Инструкция по медицинскому применению препарата Белара рег. №: П N014429/01 от 24.12.08. Бессрочно. Дата перерегистрации: 30.09.19.; Колбин А.С. COVID-19 и клиническая фармакология // Клиническая фармакология и терапия. 2020;29(3):14-24.; Вышковский Г.Л. Регистр лекарственных средств России. РЛС Энциклопедия лекарств. – М.: РЛС-ПАТЕНТ; выпуск 20/2012. – 1368 с.; Реестр лекарственных средств. Электронная энциклопедия лекарств. 2020. Доступно по: https://rlsnet/ cсылка активна на 15.12.2020; Кукес В. Г. Клиническая фармакология : учебник / под ред. В. Г. Кукеса Д. А. Сычева. – 5-е изд., испр. и доп. – Москва: ГЭОТАР-Медиа; 2017. – 1024 с.; Поиск определений во время неопределенности. Пандемия в практике гинеколога. [интернет]. Гедеон Рихтер.; Романенкова Ю.С., Кузьминова Т.И., Кызымко М.И. Влияние комбинированных оральных контрацептивов на женщин с мигренью //Акушерство, гинекология и репродукция.2018;12(1):86-92.; Унанян А.Л., Аракелов С.Э. и др. Дисменорея: практические аспекты патогенеза, клиники и терапии // «Доктор.Ру» Гинекология Эндокринология. 2014:1(89):13-17.; Driggin E, Madhavan MV, Bikdeli B et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020 May 12;75(18):2352-2371. DOI:10.1016/j.jacc.2020.03.031.; Tang N, Bai H, Chen X et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020 May;18(5):1094-1099. DOI:10.1111/jth.14817.; Громова О.А., Торшин И.Ю., Малявская С.И, Лапочкина Н.Р. О перспективах использования витамина D и других микронутриентов в профилактике и терапии COVID-19 // РМЖ. 2020;(9):32-38.; Громова О.А. Торшин И.Ю. Важность цинка для поддержания активности белков врожденного противовирусного иммунитета: анализ публикаций, посвященных COVID-19 // Профилактическая медицина. 2020;23(3):131-139.; Громова О.А., Торшин И.Ю., Учайкин В.Ф. Микронутриенты, поддерживающие врожденный иммунитет против коронавирусов: результаты систематического компьютерного анализа публикаций по COVID-19 и белков противовирусной защиты протеома человека // Фармакология & Фармакотерапия.2020;(1):9-25.; https://www.pharmacokinetica.ru/jour/article/view/255
-
13Academic Journal
Source: Репродуктивне здоров'я жінки; № 7-8 (2021); 66-70
Reproductive health of woman; № 7-8 (2021); 66-70
Reproductive health of woman; No. 7-8 (2021); 66-70Subject Terms: myomatous node, прогестагени, conservative myomectomy, норетистерон, миоматозный узел, оральные контрацептивы, progestogens, 3. Good health, міома матки, рецидив миомы, рецидив міоми, fibroid recurrence, миома матки, norethisterone, норэтистерон, міоматозний вузол, uterine fibroids, прогестагены, оральні контрацептиви, консервативна міомектомія, oral contraceptives, консервативная миомэктомия
File Description: application/pdf
Access URL: http://repro-health.com.ua/article/view/250837
-
14Academic Journal
Authors: O. S. Alyautdina
Source: Безопасность и риск фармакотерапии, Vol 0, Iss 4, Pp 17-22 (2018)
Subject Terms: комбинированные оральные контрацептивы, эстрогены, гестагены, отношение польза/риск, combined oral contraceptives, estrogens, progestins, benefir/risk ratio, Therapeutics. Pharmacology, RM1-950
File Description: electronic resource
-
15Academic Journal
Authors: Fedorova, E. S., Haperkina, I. A., Zvychainyi, M. A., Федорова, Е. С., Хаперкина, И. А., Звычайный, М. А.
Source: Сборник статей
Subject Terms: COMBINED ORAL CONTRACEPTIVES, SEXUAL FUNCTION, CONTRACEPTION, КОМБИНИРОВАННЫЕ ОРАЛЬНЫЕ КОНТРАЦЕПТИВЫ, СЕКСУАЛЬНАЯ ФУНКЦИЯ, КОНТРАЦЕПЦИЯ
File Description: application/pdf
Relation: Сборник статей "V Международная (75 Всероссийская) научно-практическая конференция "Актуальные вопросы современной медицинской науки и здравоохранения". 2020. №1; http://elib.usma.ru/handle/usma/2147
Availability: http://elib.usma.ru/handle/usma/2147
-
16Academic Journal
Authors: Dikke G.B.
Source: Проблемы репродукции
Subject Terms: premenopause, пременопауза, senior reproductive age, combined oral contraceptives, estradiol valerate, thrombosis, старший репродуктивный возраст, комбинированные оральные контрацептивы, эстрадиола валерат, тромбоз
Availability: https://openrepository.ru/article?id=244999
-
17Academic Journal
Authors: Dikke G.B.
Source: Медицинский совет
Subject Terms: folate, calcium levomefolate, drospirenone, homocysteine, combined oral contraceptives, non-contraceptive effects, protective effect, syndrome of polycystic ovaries, фолаты, левомефолат кальция, дроспиренон, гомоцистеин, комбинированные оральные контрацептивы, неконтрацептивные эффекты, протективное действие, синдром поликистозных яичников
Relation: https://doi.org/10.21518/2079-701X-2018-13-40-44; https://openrepository.ru/article?id=245727
Availability: https://openrepository.ru/article?id=245727
-
18Academic Journal
Authors: I. A. Gorlova, M. Y. Omelchenko, L. A. Sokolova, B. B. Bondarenko, И. А. Горлова, М. Ю. Омельченко, Л. А. Соколова, Б. Б. Бондаренко
Source: Translational Medicine; Том 7, № 4 (2020); 6-11 ; Трансляционная медицина; Том 7, № 4 (2020); 6-11 ; 2410-5155 ; 2311-4495 ; 10.18705/2311-4495-2020-7-4
Subject Terms: эстроген, estrogen hormone therapy, gestagen, hypercoagulation, thromboembolism, комбинированные оральные контрацептивы, гормональная терапия, гиперкоагуляция, гестаген
File Description: application/pdf
Relation: https://transmed.almazovcentre.ru/jour/article/view/551/387; Шишкова В.Н. Современная оральная контрацепция и риск тромбозов. Журнал международной медицины. 2013;1(2):56-61.; Cagnacci A. Hormonal contraception: venous and arterial disease. Eur. J. Contracept. Reprod. Health Care. 2017;22(3): 191-199.; Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular triats, and all-cause mortality: a systematic review and meta-analisis. JAMA Cardiol. 2016;1(7):767-776.; Кузнецова И.В., Суханова Г. А. Контрацепция и риск артериального тромбоза. РМЖ. Мать и дитя. 2013;23(21):1128-1133.; van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: where are we now? J. Thromb. Haemost. 2011;9(2):257-266.; Barsoum MK, Heit JA, Ashrani AA, et al. Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. Thromb. Res. 2010;126(5):373-378.; Stocco B, Fumagalli HF, Franceschini SA, et al. Comparative study of the effects of combined oral contraceptives in hemostatic variables: an observational preliminary study. Medicine. 2015; 94(4): e385.; Scarabin P-Y. Hormone therapy and venous thromboembolism among postmenopausal women. Front. Horm. Res. 2014; 43: 21-32.; Siegerink B, Maino A, Algra A, et al. Hypercoagulability and the risk of myocardial infarction and ischemic stroke in young women. J. Thromb. Haemost. 2015; 13(9): 1568-1575.; Anderson Jr FA, Spenser FA. Risk factors for venous thromboembolism. Circulation. 2003;107 (23 Suppl 1): I9-16.; Farris M, Bastianelli C, Rosato E, et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. Effects on hemostasis. Expert. Rev. Clin. Pharmacol. 2017; 10(10): 1129-1144.; Canonico M. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Maturitas. 2015; 82(3): 304-307.; Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011; 76(7): 636-652.; Atsma F, Bartelink M-LEL, Grobbee DE, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006; 13(2): 265-279.; Кузнецов М.Р., Папышева О.В. Менопаузальная гормональная терапия и венозные тромбоэмболические осложнения: какова взаимосвязь? Доктор.Ру. 2019;11(166):68-73.; Palacios S, Mejia A. Progestogen safety and tolerance in hormonal replacement therapy. Expert. Opin. Drug Saf. 2016;15(11):1515-1525.; Lidegaard 0. Severely biased review of studies assessing the risk of venous thrombosis in users of drospirenone-containing oral contraceptives. BJOG. 2018; 125(8): 929-931.; Salobir BG, Keber I, Vrabic L. A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Fertil. Steril. 2002; 78(6): 1178-1183.; Ceballos C, Ribes C, Amado JA, et al. Venous endothelial function in postmenopausal women who are receiving long-term estrogen and progestagen therapy. Fertil. Steril. 2000;74(2):268-273.; Regidor PA, Colli E, Schindler AE. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 pg per day. Gynecol. Endocrinol. 2016;32(9):749-751.; https://transmed.almazovcentre.ru/jour/article/view/551
-
19Academic Journal
Authors: N. S. Stuleva, D. A. Doronicheva, I. V. Khamani, E. A. Orudzhova, Н. С. Стулева, Д. А. Дороничева, И. В. Хамани, Э. В. Оруджова
Source: Obstetrics, Gynecology and Reproduction; Vol 14, No 4 (2020); 534-538 ; Акушерство, Гинекология и Репродукция; Vol 14, No 4 (2020); 534-538 ; 2500-3194 ; 2313-7347
Subject Terms: гипергомоцистеинемия, combined oral contraceptive, thrombotic complications, anticoagulant therapy, hemostasis disorders, venous thromboembolism, pregnancy, thrombophilia, antiphospholipid syndrome, hyperhomocysteinemia, комбинированные оральные контрацептивы, тромботические осложнения, антикоагулянтная терапия, нарушения гемостаза, венозный тромбоэмболизм, беременность, антифосфолипидный синдром
File Description: application/pdf
Relation: https://www.gynecology.su/jour/article/view/801/841; Liatsikos S. A., Tsikouras P., Manav B. et al. Inherited thrombophilia and reproductive disorders. J Turk Ger Gynecol Assoc. 2016;17(1):45–50. https://doi.org/10.5152/jtgga.2016.15212.; Макацария Н. А., Хизроева Д. Х., Бицадзе В. О. и др. Антифосфолипидные антитела у пациенток с неудачами ЭКО. Акушерство, Гинекология и Репродукция. 2014;8(4):93.; Беременность высокого риска. Под ред. А. Д. Макацария, Ф. А. Червенак, В. О. Бицадзе. М.: МИА, 2015. 920 с.; Акиньшина С. В., Макацария Н. А., Бицадзе В. О. и др. Тромбофилия и тромбоэмболические осложнения, связанные с использованием вспомогательных репродуктивных технологий. Акушерство, Гинекология и Репродукция. 2014;8(2):89–96.; Хизроева Д. Х., Михайлиди И., Стулёва Н. С. Значение определения протеина С в акушерской практике. Практическая медицина. 2013;(7):52–7.; Стулёва Н. С., Хизроева Д. Х., Машкова Т. Я., Абрамян Г. Р. Циркуляция антифосфолипидных антител и неудачи ЭКО. Акушерство, Гинекология и Репродукция. 2015;9(3):6–10. https://doi.org/10.17749/2070-4968.2015.9.3.006-010.; Peters K., Gordon N., Ricciotti N. et al. Hemostatic effects of two desogestrel-containing combined oral contraceptive regimens: a multinational, multicenter, randomized, open-label study. Clin Exp Obstet Gynecol. 2016;43(3):334–40.; Akinshina S., Makatsariya A., Bitsadze V. et al. Thromboprophylaxis in pregnant women with thrombophilia and a history of thrombosis. J Perinat Med. 2018;46(8):893–9. https://doi.org/10.1515/jpm-2017-0329.; Grandone E., Di Micco P. P., Villani М. et al. Venous thromboembolism in women undergoing assisted reproductive technologies: data from the RIETE Registry. Thromb Haemost. 2018;118(11):1962–8. https://doi.org/10.1055/s-0038-1673402.; Qublan H. S., Eid S. S., Ababneh H. A. et al. Acquired and inherited thrombophilia: implication in reccurent IVF and embryo transfer failure. Hum Reprod. 2006;21(10):2694–8. https://doi.org/10.1093/humrep/del203.; https://www.gynecology.su/jour/article/view/801
-
20Academic Journal
Authors: Окшевская Анна Андреевна, Anna A. Okshevskaia, Нестерова Надежда Викторовна, Nadezhda V. Nesterova, Бирюкова Наталья Викторовна, Natalia V. Biriukova
Source: A breakthrough in science: development strategies; 52-58 ; Новое слово в науке: стратегии развития; 52-58
Subject Terms: половое воспитание, методическая разработка, оральные контрацептивы, ЗППП
File Description: text/html
Relation: info:eu-repo/semantics/altIdentifier/isbn/978-5-6044690-4-0; https://interactive-plus.ru/e-articles/698/Action698-541061.pdf; Инфекционные заболевания и ВИЧ-инфекция / пер. с англ. под ред. С.Г. Пака, А.А. Еровиченкова, Н.Г. Кочергина. – М.: Рид Элсивер, 2010. – 296 с.; Benson M.D., Perlman C., Sciara J.J. Sex education in the inner city. JAMA. 1986; 255: 43–47.; Oakley A, Fullerton D, Holland J, et al. Sexual health education interventions for young people: A methodological review. BMJ 1995;310:158–62.; World Health Organization. Toolkit on social participation: methods and techniques for ensuring the social participation of Roma populations and other social groups in the design, implementation, monitoring and evaluation of policies and programmes to improve their health. WHO, Regional Office for Europe; 2016. 86 p.; Zanatta L.F., Moraes S.P., Freitas M.J.D., et al. Sexuality education at the itinerant school of MST: students’ perceptions. Educação e Pesquisa., (2016).; The case for addressing gender and power in sexuality and HIV education: A comprehensive review of evaluation studies. Int Perspect Sex Reprod Health. 2015; 41: 31–42.; Effects of sexuality education coaching program on sex-related knowledge and attitude among elementary school students // Journal of Korean Academy of Nursing. 2014. 44: 31–40.
